Panelists at IPWatchdog’s Virtual PTAB Masters Program 2026 last week had some cynical views on chances for pending patent reform bills, while on Friday other experts offered insights into developments at the U.S. Court of Appeals for the Federal Circuit (CAFC) with respect to review of Patent Trial and Appeal Board (PTAB) cases. Speaking on Thursday’s panel, titled “Capitol Hill & PTAB Politics: Innovation Policy, Congressional Oversight and Mid-term Elections,” panelists first addressed the chances of bills such as the Patent Eligibility Restoration Act (PERA) and the Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act advancing this year.
On Tuesday afternoon, the U.S. House of Representatives Ways and Means Committee’s Subcommittee on Trade convened a hearing titled Maintaining American Innovation and Technology Leadership, which explored a host of regulatory and other legal burdens being placed on tech industry trade by foreign governments to the detriment of American innovators and consumers. Among the panel witnesses at the subcommittee hearing was former U.S. Patent and Trademark Office (USPTO) Director Andrei Iancu, who spoke to several ways that our nation’s adversaries and trading partners alike are weakening American IP rights and how those issues should be addressed by U.S. policymakers.
The House Judiciary Committee on Tuesday considered the Protecting Third Party Litigation Funding (TPLF) From Abuse Act as part of a lengthy markup hearing that chiefly focused on escalating immigration enforcement operations in the United States. The bill did not reach a vote after committee members recessed for votes on the House floor and never reconvened. Sources tell IPWatchdog the bill has now been pulled.
As 2025 draws to a close, the intellectual property ecosystem faces a wave of transformative changes driven by artificial intelligence (AI) and evolving legislative priorities. From sweeping federal proposals aimed at harmonizing AI governance and overriding state laws, to new copyright and media integrity measures designed to address deepfakes and transparency, and finally to renewed momentum behind patent eligibility and Patent Trial and Appeal Board (PTAB) reform, these developments signal a pivotal moment for innovators, rights holders, and policymakers alike. This article explores three critical fronts shaping the future of IP: federal AI legislation and executive preemption, copyright accountability and media integrity, and the year-end outlook for patent reform—each redefining the balance between innovation, protection, and compliance.
Senators Marsha Blackburn (R-TN) and Peter Welch (D-VT) have introduced a bill to streamline the copyright registration process for visual artists, such as photographers, illustrators and graphic artists. According to a press release issued by Blackburn yesterday, “the [copyright] registration process is so bureaucratic and complicated that the time and expense of compliance is too high for high-volume creators like photographers, illustrators, and graphic artists.”
On day one of IPWatchdog’s Life Sciences Masters 2025, panelists addressed a number of looming policy proposals that are negatively impacting the life sciences industry and urged stakeholders to get involved and speak out in order to minimize their effects. An introductory panel that included program sponsors Sherry Knowles of Knowles Intellectual Property Strategies and Robert Sahr of Wolf Greenfield, as well as Becky Kaufman of Ohio State University’s Office of Legal Affairs, discussed topics including Secretary of Commerce Howard Lutnick’s patent tax proposal and the administration’s threats to march in on federally-funded university patents.
Representative Thomas Massie (R-KY) told US Inventors Conference attendees on Thursday that he will reintroduce the Restoring America’s Leadership in Innovation Act (RALIA). Massie first introduced RALIA in 2021. The bill would repeal the Patent Trial and Appeal Board (PTAB), inter partes review (IPR) and post-grant review (PGR;) return the patent system to a “first-to-invent” model, rather than first-to-file, and would end automatic publication of patents. Inventor groups such as US Inventor and conservative groups have supported the legislation.
Since its introduction in 2023, the pro-patent community has broadly supported what the draft Patent Eligibility Restoration Act (PERA) said. However, a potentially monumental, unrelated rider seems to have crept in on the last page of the 2025 version…. Why did the U.S. Senate Judiciary Committee’s Subcommittee on IP feel the need to slip in a rider on the judicially created non-statutory doctrine of obviousness-type double patenting (judicially created ODP) in a bill directed to patent eligibility?
Eight witnesses across two panels testified today during a hearing of the Senate Subcommittee on Intellectual Property to discuss perspectives on the latest version of the Patent Eligibility Restoration Act (PERA), which its key sponsor, Senator Thom Tillis (R-NC) expressed urgency about passing before he retires from congress in 452 days.
As we reported he would be yesterday, John Squires today was officially confirmed by the U.S. Senate to be the next Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office (USPTO) as part of an en bloc vote on 48 pending Trump nominees. The confirmations were made by a vote of 51-47.
On Wednesday morning, the U.S. Senate held a series of votes that teed up the confirmation vote for John Squires to serve as Director of the U.S. Patent and Trademark Office (USPTO), along with 47 other Trump Administration nominees, as part of Senate Republicans’ exercise of the “nuclear option” for confirmations recently approved by Senate rulemaking. Squires will take the helm of the USPTO following months of largely patent-friendly PTAB reforms established by Acting Director Coke Morgan Stewart, creating optimism that has recently been undercut by reported efforts to create fee frameworks based on patent valuation.
The Trump Administration is trying to counter China on nearly every strategic front, from the South China Sea to the factory floor. Yet the Administration, and Congress, haven’t yet done much to address one of America’s biggest vulnerabilities—the steady decline of our once world-class system of intellectual property (IP) rights.
On Tuesday, a coalition of business organizations and policy experts led by the U.S. Chamber of Commerce raised several concerns related to potential new patent fees they said would amount to “fines” on patent owners in a letter addressed to the bipartisan leadership of the Judiciary Committees for both houses of Congress. Echoing warnings from industry insiders about the inherent difficulties of patent valuation, the U.S. Chamber’s letter questions the Trump Administration’s legal authority to implement such fees and says that the valuation-based fee framework would be “administratively unworkable.”
Thank you for inviting Senator Tillis’ office to participate in this listening session. Panelists were asked to address an issue impacting drug affordability and accessibility. I appreciate the opportunity to share some thoughts. America’s robust intellectual property framework, most notably our patent system, is essential to fostering investments in pharmaceutical innovation and to ensuring accessibility of those medicines to benefit patients and society, both in the short and long terms. Concerns regarding drug affordability are important – as are the efforts to strengthen the patent system to ensure continued innovation now and well into the future.
Today, Senators Thom Tillis (R-NC), Chris Coons (D-DE), Marsha Blackburn (R-TN) and Adam Schiff (D-CA) introduced a bipartisan bill titled “Block Bad Electronic Art and Recording Distributors Act of 2025’’(the Block BEARD Act). The proposal is aimed at blocking foreign websites dedicated to piracy from making stolen content available to U.S. users.